毒力因子在复发性外阴阴道假丝酵母菌病中的研究进展

doi:10.3969/j.issn.1006-5725.2024.16.023

Abstract

Abstract:

Recurrent vulvovaginal candidiasis is a prevalent condition among women of reproductive age， significantly impacting their physical and mental well-being due to its recurrent nature and challenging treatment. The etiology remains elusive， while treatment options exhibit considerable variability. This paper provides a comprehensive review on the pathogenesis and therapeutic approaches targeting virulence factors associated with recurrent vulvovaginal candidiasis， aiming to offer valuable insights for understanding the underlying mechanisms and optimizing treatment strategies.

Key words: recurrent vulvovaginal candidiasis, virulence factors, pathogenesis

CLC Number:

R711.72

Yuan LI,Huiling LIU,Dan WU,Baobao. LI. Research advances of virulence factors in recurrent vulvovaginal candidiasis[J]. The Journal of Practical Medicine, 2024, 40(16): 2347-2351.

References 45

1	GONÇALVES B， FERREIRA C， ALVES C T， et al. Vulvovaginal candidiasis：Epidemiology， microbiology and risk factors［J］. Crit Rev Microbiol， 2016， 42（6）：905-927. doi:10.3109/1040841x.2015.1091805 doi: 10.3109/1040841x.2015.1091805
2	DENNING D W， KNEALE M， SOBEL J D， et al.Global burden of recurrent vulvovaginal candidiasis：a systematic review［J］. Lancet Infect Dis， 2018， 18（11）：339-347. doi:10.1016/s1473-3099(18)30103-8 doi: 10.1016/s1473-3099(18)30103-8
3	SHERRARD J， WILSON J， DONDERS G， et al.2018 European（IUSTI/WHO）International Union against sexually transmitted infections（IUSTI）World Health Organisation（WHO）guideline on the management of vaginal discharge［J］. Int J STD AIDS， 2018， 29（13）：1258-1272. doi:10.1177/0956462418785451 doi: 10.1177/0956462418785451
4	JULIANA L， CÉSAR P G， CRISTINE A S， et al.Antifungal （oral and vaginal） therapy for recurrent vulvovaginal candidiasis： a systematic review and meta-analysis［J］. Rev Assoc Med Bras （1992）， 2022， 68（2）：261-267. doi:10.1590/1806-9282.20210916 doi: 10.1590/1806-9282.20210916
5	ARDIZZONI A， WHEELER R T， PERICOLINI E. It Takes Two to Tango： How a Dysregulation of the Innate Immunity， Coupled With Candida Virulence， Triggers VVC Onset［J］. Front Microbiol， 2021， 12：692491. doi:10.3389/fmicb.2021.692491 doi: 10.3389/fmicb.2021.692491
6	CASSONE A. Vulvovaginal Candida albicans infections： pathogenesis， immunity and vaccine prospects［J］. BJOG， 2015， 122（6）：785-794. doi:10.1111/1471-0528.12994 doi: 10.1111/1471-0528.12994
7	WORKOWSKI K A， BOLAN G A. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines， 2015［J］. MMWR Recomm Rep， 2015， 64（3）：77.
8	WORKOWSKI K A， BACHMANN L H， CHAN P A， et al. Sexually transmitted infections treatment guidelines， 2021［J］. MMWR Recomm Rep， 2021， 70（4）：93. doi:10.15585/mmwr.rr7004a1 doi: 10.15585/mmwr.rr7004a1
9	SAXON L A G， EDWARDS A， RAUTEMAA-RICHARDSON R， et al. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis（2019）［J］. Int JSTD AIDS， 2020， 31（12）：1124-1144. doi:10.1177/0956462420943034 doi: 10.1177/0956462420943034
10	VAN SCHALKWYK J， YUDIN M H. Vulvovaginitis：screening for and management of trichomoniasis， vulvovaginal candidiasis， and bacterial vaginosis［J］. J Obstet Gynaecol Can， 2015， 37（3）： 266-274. doi:10.1016/s1701-2163(15)30316-9 doi: 10.1016/s1701-2163(15)30316-9
11	中华医学会妇产科学分会感染性疾病协作组. 外阴阴道假丝酵母菌病（VVC）诊治规范修订稿［J］. 中国实用妇科与产科杂志， 2012， 28（6）：401-402.
12	ALEX F， ISAAK E， BRIGITTE T F， et al. Guideline： Vulvovaginal candidosis （AWMF 015/072， level S2k）［J］. Mycoses， 2021， 64（6）：583-602. doi:10.1111/myc.13248 doi: 10.1111/myc.13248
13	LIU C， XU C， DU Y， et al. Role of agglutinin-like sequence protein 3 （Als3） in the structure and antifungal resistance of Candida albicans biofilms［J］. FEMS Microbiol Lett， 2021，368（14）：fnab089. doi:10.1093/femsle/fnab089 doi: 10.1093/femsle/fnab089
14	CHEN H， ZHOU X， REN B， et al. The regulation of hyphae growth in Candida albicans［J］. Virulence， 2020， 11（1）：337-348. doi:10.1080/21505594.2020.1748930 doi: 10.1080/21505594.2020.1748930
15	CHOW E W L， PANG L M， WANG Y. From Jekyll to Hyde： The Yeast-Hyphal Transition of Candida albicans［J］. Pathogens， 2021，10（7）：859. doi:10.3390/pathogens10070859 doi: 10.3390/pathogens10070859
16	PRASAD P， TIPPANA M. Morphogenic plasticity： the pathogenic attribute of Candida albicans［J］. Curr Genet， 2023， 69（2-3）：77-89. doi:10.1007/s00294-023-01263-5 doi: 10.1007/s00294-023-01263-5
17	DUNKER C， POLKE M， SCHULZE-RICHTER B， et al. Rapid proliferation due to better metabolic adaptation results in full virulence of a filament-deficient Candida albicans strain［J］. Nat Commun， 2021， 12（1）：3899-3899. doi:10.1038/s41467-021-24095-8 doi: 10.1038/s41467-021-24095-8
18	牟一凡，史文华，沈影，等. 阴道白假丝酵母菌生物膜形成、免疫逃避策略及治疗思路的研究进展［J］. 现代妇产科进展， 2021， 30（12）：945-947.
19	LOHSE M B， GULATI M， JOHNSON A D， et al. Development and regulation of single- and multi-species Candida albicans biofilms［J］. Nat Rev Microbiol， 2018， 16（1）：19-31. doi:10.1038/nrmicro.2017.107 doi: 10.1038/nrmicro.2017.107
20	和平安，杨旭，吕梅，等. 白假丝酵母菌生物膜的研究进展［J］.中国微生态学志， 2020， 32（10）：1238-1241. doi:10.13381/j.cnki.cjm.202010027 doi: 10.13381/j.cnki.cjm.202010027
21	PAN Y， SUN Y， CHEN L， et al. Candida causes recurrent vulvovaginal candidiasis by forming morphologically disparate biofilms on the human vaginal epithelium［J］. Biofilm， 2023， 6：100162. doi:10.1016/j.bioflm.2023.100162 doi: 10.1016/j.bioflm.2023.100162
22	解寻，孔晋亮，罗劲，等. 中药对耐药菌生物膜抑制作用的研究进展［J］. 实用医学杂志， 2021， 37（21）：2813-2816. doi:10.3969/j.issn.1006-5725.2021.21.022 doi: 10.3969/j.issn.1006-5725.2021.21.022
23	PEREIRA R， DOS SANTOS FONTENELLE R O， DE BRITO E H S， et al. Biofilm of Candida albicans： formation， regulation and resistance［J］. J Appl Microbiol， 2020， 131（1）：11-22. doi:10.1111/jam.14949 doi: 10.1111/jam.14949
24	PERLIN D S. Cell Wall-Modifying Antifungal Drugs［J］. Curr Top Microbiol Immunol， 2020， 425：255-275. doi:10.1007/82_2019_188 doi: 10.1007/82_2019_188
25	FARIA-GONÇALVES P， ROLO J， GASPAR C， et al. Virulence Factors as Promoters of Chronic Vulvovaginal Candidosis： A Review［J］. Mycopathologia， 2021， 186（6）：755-773. doi:10.1007/s11046-021-00592-8 doi: 10.1007/s11046-021-00592-8
26	BARMAN A， GOHAIN D， BORA U， et al. Phospholipases play multiple cellular roles including growth， stress tolerance， sexual development， and virulence in fungi［J］. Microbiol Res， 2018， 209：55-69. doi:10.1016/j.micres.2017.12.012 doi: 10.1016/j.micres.2017.12.012
27	FARIA-GONÇALVES P， ROLO J， GASPAR C， et al. Recurrent vulvovaginal Candida spp isolates phenotypically express less virulence traits［J］. Microbial Pathog， 2020， 148：104471. doi:10.1016/j.micpath.2020.104471 doi: 10.1016/j.micpath.2020.104471
28	SHAO M K， QI W J， HOU M Y， et al. Analysis of pathogenic factors of Candida albicans and the effect of vaginal immunization on recurrent vulvovaginal candidiasis in mice［J］. J Obstet Gynaecol Res， 2022， 48（3）：857-865. doi:10.1111/jog.15140 doi: 10.1111/jog.15140
29	MOYES D L， WILSON D， RICHARDSON J P， et al. Candidalysin is a fungal peptide toxin critical for mucosal infectionCandidalysin is a fungal peptide toxin critical for mucosal infection［J］. Nature， 2016， 532（7597）：64-68.
30	BLAGOJEVIC M， CAMILLI G， MAXSON M， et al. Candidalysin triggers epithelial cellular stresses that induce necrotic death［J］. Cell Microbiol， 2021， 23（10）：e13371. doi:10.1111/cmi.13371 doi: 10.1111/cmi.13371
31	OLIVIER F A B， HILSENSTEIN V， WEERASINGHE H， et al.The escape of Candida albicans from macrophages is enabled by the fungal toxin candidalysin and two host cell death pathways［J］. Cell Rep， 2022， 40（12）：111374. doi:10.1016/j.celrep.2022.111374 doi: 10.1016/j.celrep.2022.111374
32	杨艳华，陈佳仪，陈妍，等. 阴道白念珠菌毒力因子表达水平及与耐药的相关性［J］. 中国热带医学， 2022， 22（5）：423-428.
33	GRANT L M， ORENSTEIN R. Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp［J］. J Investig Med High Impact Case Rep， 2022， 10：23247096221123144. doi:10.1177/23247096221123144 doi: 10.1177/23247096221123144
34	刘锦燕，郑彧鸣，项明洁. 新型抗真菌药物研发进展及其作用靶点机制［J］. 中国感染与化疗杂志， 2023， 23（1）：121-125.
35	ClinicalTrials.gov. Phase 3 study of oral ibrexafungerp （SCY- 078vs）. placebo in subjects with recurrent vulvovaginal candidiasis （VVC）（CANDLE）［EB/OL］.［2023-12-06］. . doi:10.31525/ct1-nct04029116 doi: 10.31525/ct1-nct04029116
36	PHILLIPS N A， BACHMANN G， HAEFNER H， et al. Topical Treatment of Recurrent Vulvovaginal Candidiasis： An Expert Consensus［J］. Womens Health Rep （New Rochelle）， 2022， 3（1）：38-42. doi:10.1089/whr.2021.0065 doi: 10.1089/whr.2021.0065
37	ALVENDAL C， MOHANTY S， BOHM-STARKE N， et al. Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates［J］. PLoS One， 2020，15（9）：e0238428. doi:10.1371/journal.pone.0238428 doi: 10.1371/journal.pone.0238428
38	WOODBURN K W， CLEMENS L E， JAYNES J， et al. Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment［J］. Antimicrob Agents Chemother， 2019， 63（11）：e02690-18. doi:10.1128/aac.02690-18 doi: 10.1128/aac.02690-18
39	NIKOOMANESH F， FALAHATINEJAD M， ČERNÁKOVÁ L， et al. Combination of Farnesol with Common Antifungal Drugs： Inhibitory Effect against Candida Species Isolated from Women with RVVC［J］. Medicina （Kaunas）， 2023， 59（4）：743. doi:10.3390/medicina59040743 doi: 10.3390/medicina59040743
40	DE BERNARDIS F， SANTONI G， BOCCANERA M， et al. Protection against rat vaginal Candidiasis by adoptive transfer of vaginal B lymphocytes［J］. FEMS Yeast Res， 2010， 10： 432-440. doi:10.1111/j.1567-1364.2010.00620.x doi: 10.1111/j.1567-1364.2010.00620.x
41	DONDERS G， SZILLER I O， PAAVONEN J， et al. Management of recurrent vulvovaginal candidosis： Narrative review of the literature and European expert panel opinion［J］. Front Cell Infect Microbiol， 2022， 12：934353. doi:10.3389/fcimb.2022.934353 doi: 10.3389/fcimb.2022.934353
42	DE BERNARDIS F， GRAZIANI S， TIRELLI F， et al. Candida vaginitis： virulence， host response and vaccine prospects［J］. Med Mycol， 2018， 56（S1）：26-31. doi:10.1093/mmy/myx139 doi: 10.1093/mmy/myx139
43	HONORATO L， DE ARAUJO J F D， ELLIS C C， et al. Extracellular Vesicles Regulate Biofilm Formation and Yeast-to-Hypha Differentiation in Candida albicans［J］. mBio，2022，13（3）：e0030122. doi:10.1128/mbio.00301-22 doi: 10.1128/mbio.00301-22
44	YUAN R， TU J， SHENG C， CHEN X， et al. Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans［J］. Front Microbiol， 2021， 12：680382. doi:10.3389/fmicb.2021.680382 doi: 10.3389/fmicb.2021.680382
45	CHARPAK-AMIKAM Y， LAPIDUS T， ISAACSON B， et al. Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT［J］. Nat Commun， 2022， 13（1）：2463-2463. doi:10.1038/s41467-022-30087-z doi: 10.1038/s41467-022-30087-z

[1]	GUO Haiwen, YU Shaowei.. Research progress in diagnosis of specific learning disorder [J]. The Journal of Practical Medicine, 2023, 39(4): 395-399.
[2]	Jianfeng ZHANG,Bin YU,Zhenya ZHANG,Guiying. WANG. Advances in the diagnosis and treatment of postoperative delirium in colorectal cancer [J]. The Journal of Practical Medicine, 2023, 39(20): 2687-2690.
[3]	HUANG Ying, TANG Lili, GUAN Yulin, ZHANG Jie, LI Xiaoyue.. Research progress on the pathogenesis and treatment of sepsis⁃induced myocardial injury [J]. The Journal of Practical Medicine, 2023, 39(14): 1848-1852.
[4]	MA Ying, HUANG Sixia, HUANG Liujing, CAI Zhaoxia, MA Song, LIANG Xiaoshan.. Microbiomics：A new direction in etiology of endometriosis [J]. The Journal of Practical Medicine, 2022, 38(24): 3027-3031.
[5]	ZHONG Rongbin, RAO Ming⁃ cong , HUANG Minfang.. Research progress in comorbidity of obstructive sleep apnea with insomnia [J]. The Journal of Practical Medicine, 2022, 38(2): 134-138.
[6]	LI Ying, LI Qing, WANG Xuan, ZHOU Lijun, TAN Zhi. . Research advances in burning mouth syndrome [J]. The Journal of Practical Medicine, 2022, 38(19): 2486-2490.
[7]	LI Li, ZHOU Jiahe, LI Mojuan, ZHONG Minglin, ZHANG Xiaowei, XU Qiuyi, LIANG Li⁃ anyun.. A frontier review and an outlook on epigenetics，metabolomics，and gut microbiota mechanism of polycystic ovary syndrome [J]. The Journal of Practical Medicine, 2022, 38(16): 1987-1992.
[8]	YE Mingjun, DAI Yong, TANG Donge, LI Qiang, YIN Lianghong.. Research progress of metabonomics in peritoneal dialysis [J]. The Journal of Practical Medicine, 2022, 38(1): 1-6.
[9]	LI Ying, LI Canwei, FAN Mengran, LIU Wei⁃ hong, GAO Pengfei. Metabolomics research progress on alcoholic liver disease [J]. The Journal of Practical Medicine, 2021, 37(7): 944-947.
[10]	JIANG Longyuan. Research Advances in the role of immunodeficiency in Sepsis [J]. The Journal of Practical Medicine, 2021, 37(6): 701-704.
[11]	YAO Chaoyi, ZHANG Yide. New progress in the pathogenesis of type IV cardiorenal syndrome [J]. The Journal of Practical Medicine, 2021, 37(4): 542-546.
[12]	ZHANG Tong, CAI Jinchi, YUAN Zhifa, ZHAO Haiyan, WANG Wenji. Postoperative vision loss after spine surgery caused by ischemic optic neuropathy：A literature review [J]. The Journal of Practical Medicine, 2021, 37(2): 129-133.

Research advances of virulence factors in recurrent vulvovaginal candidiasis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 45

Related Articles 12

Recommended Articles

Metrics

Comments